首页 > 最新文献

Emergency Medicine Australasia最新文献

英文 中文
Impact of lifeguard oxygen therapy on the resuscitation of drowning victims: Results from an Utstein Style for Drowning Study. 救生员氧疗对溺水者复苏的影响:乌特斯坦溺水风格研究的结果。
IF 1.7 4区 医学 Q2 EMERGENCY MEDICINE Pub Date : 2024-06-20 DOI: 10.1111/1742-6723.14454
Ogilvie Thom, Kym Roberts, Susan Devine, Peter A Leggat, Richard C Franklin

Introduction: No published evidence was identified regarding the use of oxygen in the treatment of drowning in two recent systematic reviews. The aim of our study was to investigate the impact of on scene, pre-Emergency Medical Services (EMS) oxygen therapy by lifeguards in the resuscitation of drowning victims.

Method: We conducted a retrospective case match analysis of drowning patients presenting to the EDs of Sunshine Coast Hospital and Health Service. Patients were matched for age, sex and severity of drowning injury. The primary outcome was in-hospital mortality. Secondary outcomes included positive pressure ventilation (PPV) by EMS and the ED, as well as admission to the Intensive Care Unit.

Results: There were 108 patients in each group. Median (IQR) age was 22 (15-43) in the oxygen group and 23 (15-44) years in the non-oxygen group. There were 45 females in the oxygen group and 41 females in the non-oxygen group. Sixteen patients had suffered cardiac arrest and three patients respiratory arrest in each group. There were five deaths in each group. Initial oxygen saturation on arrival of EMS was identical in both groups 89.2% (±19.9) in the oxygen group versus 89.3% (±21.1) (P = 0.294) in the non-oxygen group. The oxygen group required PPV more frequently with EMS (19 vs 11, P < 0.01) and in the ED (19 vs 15, P < 0.01).

Conclusion: On scene treatment with oxygen by lifeguards did not improve oxygenation or outcomes in drowning patients.

导言:在最近的两篇系统综述中,没有发现有关使用氧气治疗溺水的公开证据。我们的研究旨在调查救生员在现场进行紧急医疗服务(EMS)前氧气治疗对溺水者复苏的影响:我们对阳光海岸医院和卫生服务机构急诊室的溺水患者进行了回顾性病例匹配分析。患者的年龄、性别和溺水伤害的严重程度均匹配。主要结果是院内死亡率。次要结果包括急救中心和急诊室的正压通气(PPV)以及重症监护室的入院情况:每组共有 108 名患者。氧气组的中位(IQR)年龄为 22(15-43)岁,非氧气组为 23(15-44)岁。氧气组有 45 名女性,无氧组有 41 名女性。每组中有 16 名患者心跳停止,3 名患者呼吸停止。两组各有 5 人死亡。两组急救人员到达时的初始血氧饱和度相同,氧气组为 89.2%(±19.9),非氧气组为 89.3%(±21.1)(P = 0.294)。氧气组需要急救人员进行 PPV 的次数更多(19 对 11,P 结论:氧气组需要急救人员进行 PPV 的次数更多:救生员在现场提供氧气并不能改善溺水患者的氧合情况或预后。
{"title":"Impact of lifeguard oxygen therapy on the resuscitation of drowning victims: Results from an Utstein Style for Drowning Study.","authors":"Ogilvie Thom, Kym Roberts, Susan Devine, Peter A Leggat, Richard C Franklin","doi":"10.1111/1742-6723.14454","DOIUrl":"10.1111/1742-6723.14454","url":null,"abstract":"<p><strong>Introduction: </strong>No published evidence was identified regarding the use of oxygen in the treatment of drowning in two recent systematic reviews. The aim of our study was to investigate the impact of on scene, pre-Emergency Medical Services (EMS) oxygen therapy by lifeguards in the resuscitation of drowning victims.</p><p><strong>Method: </strong>We conducted a retrospective case match analysis of drowning patients presenting to the EDs of Sunshine Coast Hospital and Health Service. Patients were matched for age, sex and severity of drowning injury. The primary outcome was in-hospital mortality. Secondary outcomes included positive pressure ventilation (PPV) by EMS and the ED, as well as admission to the Intensive Care Unit.</p><p><strong>Results: </strong>There were 108 patients in each group. Median (IQR) age was 22 (15-43) in the oxygen group and 23 (15-44) years in the non-oxygen group. There were 45 females in the oxygen group and 41 females in the non-oxygen group. Sixteen patients had suffered cardiac arrest and three patients respiratory arrest in each group. There were five deaths in each group. Initial oxygen saturation on arrival of EMS was identical in both groups 89.2% (±19.9) in the oxygen group versus 89.3% (±21.1) (P = 0.294) in the non-oxygen group. The oxygen group required PPV more frequently with EMS (19 vs 11, P < 0.01) and in the ED (19 vs 15, P < 0.01).</p><p><strong>Conclusion: </strong>On scene treatment with oxygen by lifeguards did not improve oxygenation or outcomes in drowning patients.</p>","PeriodicalId":11604,"journal":{"name":"Emergency Medicine Australasia","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health consumers' ethical concerns towards artificial intelligence in Australian emergency departments 医疗消费者对澳大利亚急诊科人工智能的伦理关注。
IF 1.7 4区 医学 Q2 EMERGENCY MEDICINE Pub Date : 2024-06-18 DOI: 10.1111/1742-6723.14449
Sam Freeman PhD, Jonathon Stewart MBBS, MMed(CritCare), Rebecca Kaard, Eden Ouliel, Adrian Goudie MBBS FACEM DDU, Girish Dwivedi MD, PhD, FRACP, Hamed Akhlaghi MD, PhD, FACEM

Objectives

To investigate health consumers' ethical concerns towards the use of artificial intelligence (AI) in EDs.

Methods

Qualitative semi-structured interviews with health consumers, recruited via health consumer networks and community groups, interviews conducted between January and August 2022.

Results

We interviewed 28 health consumers about their perceptions towards the ethical use of AI in EDs. The results discussed in this paper highlight the challenges and barriers for the effective and ethical implementation of AI from the perspective of Australian health consumers. Most health consumers are more likely to support AI health tools in EDs if they continue to be involved in the decision-making process. There is considerably more approval of AI tools that support clinical decision-making, as opposed to replacing it. There is mixed sentiment about the acceptability of AI tools influencing clinical decision-making and judgement. Health consumers are mostly supportive of the use of their data to train and develop AI tools but are concerned with who has access. Addressing bias and discrimination in AI is an important consideration for some health consumers. Robust regulation and governance are critical for health consumers to trust and accept the use of AI.

Conclusion

Health consumers view AI as an emerging technology that they want to see comprehensively regulated to ensure it functions safely and securely with EDs. Without considerations made for the ethical design, implementation and use of AI technologies, health consumer trust and acceptance in the use of these tools will be limited.

目的调查医疗消费者对在急诊室使用人工智能(AI)的伦理关切:通过健康消费者网络和社区团体招募健康消费者,对其进行半结构化定性访谈,访谈于 2022 年 1 月至 8 月间进行:我们对 28 位健康消费者进行了访谈,了解他们对 ED 中使用人工智能的道德观念。本文讨论的结果强调了从澳大利亚健康消费者的角度来看,有效和合乎道德地实施人工智能所面临的挑战和障碍。如果大多数医疗消费者能够继续参与决策过程,他们就更有可能支持在急诊室使用人工智能医疗工具。支持临床决策而非取代临床决策的人工智能工具得到了更多的认可。对于人工智能工具影响临床决策和判断的可接受性,人们的看法不一。医疗消费者大多支持使用他们的数据来训练和开发人工智能工具,但对谁能使用这些工具表示担忧。解决人工智能中的偏见和歧视是一些健康消费者的重要考虑因素。健全的监管和治理对于健康消费者信任和接受人工智能的使用至关重要:健康消费者认为人工智能是一种新兴技术,他们希望看到对其进行全面监管,以确保其安全可靠地与 ED 一起发挥作用。如果不考虑人工智能技术设计、实施和使用的道德问题,健康消费者对使用这些工具的信任和接受程度将受到限制。
{"title":"Health consumers' ethical concerns towards artificial intelligence in Australian emergency departments","authors":"Sam Freeman PhD,&nbsp;Jonathon Stewart MBBS, MMed(CritCare),&nbsp;Rebecca Kaard,&nbsp;Eden Ouliel,&nbsp;Adrian Goudie MBBS FACEM DDU,&nbsp;Girish Dwivedi MD, PhD, FRACP,&nbsp;Hamed Akhlaghi MD, PhD, FACEM","doi":"10.1111/1742-6723.14449","DOIUrl":"10.1111/1742-6723.14449","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To investigate health consumers' ethical concerns towards the use of artificial intelligence (AI) in EDs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Qualitative semi-structured interviews with health consumers, recruited via health consumer networks and community groups, interviews conducted between January and August 2022.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We interviewed 28 health consumers about their perceptions towards the ethical use of AI in EDs. The results discussed in this paper highlight the challenges and barriers for the effective and ethical implementation of AI from the perspective of Australian health consumers. Most health consumers are more likely to support AI health tools in EDs if they continue to be involved in the decision-making process. There is considerably more approval of AI tools that support clinical decision-making, as opposed to replacing it. There is mixed sentiment about the acceptability of AI tools influencing clinical decision-making and judgement. Health consumers are mostly supportive of the use of their data to train and develop AI tools but are concerned with who has access. Addressing bias and discrimination in AI is an important consideration for some health consumers. Robust regulation and governance are critical for health consumers to trust and accept the use of AI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Health consumers view AI as an emerging technology that they want to see comprehensively regulated to ensure it functions safely and securely with EDs. Without considerations made for the ethical design, implementation and use of AI technologies, health consumer trust and acceptance in the use of these tools will be limited.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11604,"journal":{"name":"Emergency Medicine Australasia","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1742-6723.14449","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nationwide status of aeromedical pre-hospital and retrieval medicine in Australia 澳大利亚全国航空医疗入院前和回收医学现状。
IF 1.7 4区 医学 Q2 EMERGENCY MEDICINE Pub Date : 2024-06-05 DOI: 10.1111/1742-6723.14448
John Hollott BMed, FANZCA, FAWM, Scott Gelzinnis MD, BMedSci, BMus, Mary Morgan BHB, MBChB, FACEM, AFRACMA, MBA, Alan Garner OAM, MBBS, FACEM, MSc, PhD

Objective

To survey the current structure, capability and operational scope of pre-hospital and retrieval aeromedical teams across Australia.

Methods

The medical directors of all Australian civilian adult aeromedical retrieval organisations with pre-hospital teams and/or doctors for inter-hospital critical care patient transport were contacted in a survey to qualitatively assess capacity and team structure.

Results

All 17 organisations contacted completed the survey. While there is diversity in team structure with the pairing of doctors, paramedics and nurses, capacity for patient care is generally homogenous. A doctor/paramedic model is the more common team structure for rotary-wing missions, and doctor/nurse for fixed-wing. Differences are mostly due to state government controlled aspects of their health services. An advanced degree of intensive patient care occurs outside of the hospital. Land and sea rescue is an important aspect of Australian aeromedical work.

Conclusion

Aeromedicine in Australia has many consistent elements, but variable contexts have resulted in a diversity of operational models.

目的调查澳大利亚各地院前和回收航空医疗团队的当前结构、能力和业务范围:调查联系了所有拥有院前团队和/或医院间危重病人转运医生的澳大利亚民用成人航空医疗救护组织的医疗总监,对能力和团队结构进行定性评估:所联系的 17 家机构全部完成了调查。虽然医生、辅助医务人员和护士搭配的团队结构多种多样,但病人护理能力却普遍单一。医生/辅助医务人员模式是旋转翼飞行任务中较为常见的团队结构,而医生/护士模式则是固定翼飞行任务中较为常见的团队结构。不同之处主要在于州政府对其医疗服务的控制。医院外也有高级别的重症病人护理。陆地和海上救援是澳大利亚航空医疗工作的一个重要方面:结论:澳大利亚的航空医疗有许多一致的要素,但不同的背景导致了运作模式的多样性。
{"title":"Nationwide status of aeromedical pre-hospital and retrieval medicine in Australia","authors":"John Hollott BMed, FANZCA, FAWM,&nbsp;Scott Gelzinnis MD, BMedSci, BMus,&nbsp;Mary Morgan BHB, MBChB, FACEM, AFRACMA, MBA,&nbsp;Alan Garner OAM, MBBS, FACEM, MSc, PhD","doi":"10.1111/1742-6723.14448","DOIUrl":"10.1111/1742-6723.14448","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To survey the current structure, capability and operational scope of pre-hospital and retrieval aeromedical teams across Australia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The medical directors of all Australian civilian adult aeromedical retrieval organisations with pre-hospital teams and/or doctors for inter-hospital critical care patient transport were contacted in a survey to qualitatively assess capacity and team structure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>All 17 organisations contacted completed the survey. While there is diversity in team structure with the pairing of doctors, paramedics and nurses, capacity for patient care is generally homogenous. A doctor/paramedic model is the more common team structure for rotary-wing missions, and doctor/nurse for fixed-wing. Differences are mostly due to state government controlled aspects of their health services. An advanced degree of intensive patient care occurs outside of the hospital. Land and sea rescue is an important aspect of Australian aeromedical work.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Aeromedicine in Australia has many consistent elements, but variable contexts have resulted in a diversity of operational models.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11604,"journal":{"name":"Emergency Medicine Australasia","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Repeated intentional foreign body ingestion, what can be done? 反复故意摄入异物,该怎么办?
IF 1.7 4区 医学 Q2 EMERGENCY MEDICINE Pub Date : 2024-06-04 DOI: 10.1111/1742-6723.14451
Paris Hoey MBBS, Kimberley Ryan BN, MN, Clancy McDonald BN, MNP, Nathan J Brown PhD, Kym Boon MBBS, FRANZCP, FFPMANZA, Florian Grimpen MD, FRACP, Mark Appleyard MBBS, FRACP

Repeated intentional foreign body ingestion (RIFBI) in patients with Emotionally Unstable Personality Disorder (EUPD) is a common clinical presentation to the emergency department. The relationship between repeated foreign body ingestion and a co-existent personality disorder diagnosis is complex, making it challenging to manage. Our institution implemented a novel interdisciplinary model of care for RIFBI as a way of improving health outcomes in this cohort of patients. Our observations following the model of care are presented herein. We encourage other health networks to adopt this model of care for managing RIBFI in EUPD.

情绪不稳定型人格障碍(EUPD)患者反复故意吞食异物(RIFBI)是急诊科常见的临床表现。反复异物摄入与同时存在的人格障碍诊断之间的关系十分复杂,因此处理起来具有挑战性。我院针对 RIFBI 实施了一种新颖的跨学科护理模式,以改善这类患者的健康状况。本文介绍了我们对该护理模式的观察结果。我们鼓励其他医疗网络采用这种护理模式来管理欧盟精神疾病患者的 RIBFI。
{"title":"Repeated intentional foreign body ingestion, what can be done?","authors":"Paris Hoey MBBS,&nbsp;Kimberley Ryan BN, MN,&nbsp;Clancy McDonald BN, MNP,&nbsp;Nathan J Brown PhD,&nbsp;Kym Boon MBBS, FRANZCP, FFPMANZA,&nbsp;Florian Grimpen MD, FRACP,&nbsp;Mark Appleyard MBBS, FRACP","doi":"10.1111/1742-6723.14451","DOIUrl":"10.1111/1742-6723.14451","url":null,"abstract":"<p>Repeated intentional foreign body ingestion (RIFBI) in patients with Emotionally Unstable Personality Disorder (EUPD) is a common clinical presentation to the emergency department. The relationship between repeated foreign body ingestion and a co-existent personality disorder diagnosis is complex, making it challenging to manage. Our institution implemented a novel interdisciplinary model of care for RIFBI as a way of improving health outcomes in this cohort of patients. Our observations following the model of care are presented herein. We encourage other health networks to adopt this model of care for managing RIBFI in EUPD.</p>","PeriodicalId":11604,"journal":{"name":"Emergency Medicine Australasia","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Virtual Toxicology Service decreases the average length of stay of poisoned patients and saves bed days 虚拟毒理学服务缩短了中毒病人的平均住院时间,节省了住院日。
IF 1.7 4区 医学 Q2 EMERGENCY MEDICINE Pub Date : 2024-06-04 DOI: 10.1111/1742-6723.14453
Iain McNeill MBChB, FACEM, Andrew Staib MBBS, PhD, Katherine Z Isoardi BMed, FACEM

Objective

We aimed to assess the impact a Virtual Toxicology Service had on the ALOS of poisoned patients.

Methods

This single-centre before-after study compares the ALOS of poisoned patients (diagnosis-related group X62, poisoning/toxic effects of drugs and other substances) following the introduction of a Virtual Toxicology Service in 2020.

Results

The ALOS decreased from 0.89 days in the 2-year pre-intervention period to 0.62 days in the 3-year post-intervention period, with a potential bed saving of 703 days.

Conclusion

The introduction of a Virtual Toxicology Service appeared to be associated with a decreased ALOS of poisoned patients.

目的:我们旨在评估虚拟毒理学服务对中毒患者 ALOS 的影响:我们旨在评估虚拟毒理学服务对中毒患者ALOS的影响:这项单中心研究比较了 2020 年引入虚拟毒理学服务后中毒患者(诊断相关组 X62,药物和其他物质中毒/毒性作用)的 ALOS:结果:ALOS从干预前2年的0.89天减少到干预后3年的0.62天,潜在节省床位703天:结论:虚拟毒理学服务的引入似乎与中毒患者 ALOS 的减少有关。
{"title":"Virtual Toxicology Service decreases the average length of stay of poisoned patients and saves bed days","authors":"Iain McNeill MBChB, FACEM,&nbsp;Andrew Staib MBBS, PhD,&nbsp;Katherine Z Isoardi BMed, FACEM","doi":"10.1111/1742-6723.14453","DOIUrl":"10.1111/1742-6723.14453","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>We aimed to assess the impact a Virtual Toxicology Service had on the ALOS of poisoned patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This single-centre before-after study compares the ALOS of poisoned patients (diagnosis-related group X62, poisoning/toxic effects of drugs and other substances) following the introduction of a Virtual Toxicology Service in 2020.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The ALOS decreased from 0.89 days in the 2-year pre-intervention period to 0.62 days in the 3-year post-intervention period, with a potential bed saving of 703 days.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The introduction of a Virtual Toxicology Service appeared to be associated with a decreased ALOS of poisoned patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11604,"journal":{"name":"Emergency Medicine Australasia","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1742-6723.14453","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Just a head knock? Emergency physicians need to get serious about concussion. 只是头部撞击?急诊医生需要认真对待脑震荡。
IF 2.3 4区 医学 Q2 Medicine Pub Date : 2024-06-04 DOI: 10.1111/1742-6723.14452
Alan J Pearce, Peter Wirth, Michelle Fitts

Attention and awareness regarding concussion injury in Australia have significantly increased in the last decade. Although most of this increase is because of discussion regarding concussions from sporting endeavours, the majority of concussions are from non-sport environments including motor vehicle crashes, workplace incidents, falls, accidents, assault and intimate partner violence. In all cases, hospital EDs are the first point of contact, yet as argued in our Opinion here, there are concerns regarding the consistency of care protocols, because of a number of reasons, as well as management and follow-up clinical practices. Our Opinion is to provide a constructive discussion as well as calling for ACEM to support research to provide evidence-based data. Finally, we provide some recommendations that could be implemented immediately to improve clinical practice for presentations of concussion injuries in EDs.

在过去十年中,澳大利亚对脑震荡伤害的关注和认识有了显著提高。尽管这种增长主要是由于有关体育运动造成脑震荡的讨论,但大多数脑震荡是在非体育运动环境中造成的,包括机动车碰撞、工作场所事故、跌倒、意外事故、攻击和亲密伴侣暴力。在所有情况下,医院急诊室都是第一接触点,但正如我们在此发表的《意见》中所论述的,由于多种原因,人们对护理方案的一致性以及管理和后续临床实践存在担忧。我们的意见旨在提供建设性的讨论,并呼吁 ACEM 支持研究,以提供循证数据。最后,我们提出了一些可立即实施的建议,以改善急诊室脑震荡损伤的临床实践。
{"title":"Just a head knock? Emergency physicians need to get serious about concussion.","authors":"Alan J Pearce, Peter Wirth, Michelle Fitts","doi":"10.1111/1742-6723.14452","DOIUrl":"https://doi.org/10.1111/1742-6723.14452","url":null,"abstract":"<p><p>Attention and awareness regarding concussion injury in Australia have significantly increased in the last decade. Although most of this increase is because of discussion regarding concussions from sporting endeavours, the majority of concussions are from non-sport environments including motor vehicle crashes, workplace incidents, falls, accidents, assault and intimate partner violence. In all cases, hospital EDs are the first point of contact, yet as argued in our Opinion here, there are concerns regarding the consistency of care protocols, because of a number of reasons, as well as management and follow-up clinical practices. Our Opinion is to provide a constructive discussion as well as calling for ACEM to support research to provide evidence-based data. Finally, we provide some recommendations that could be implemented immediately to improve clinical practice for presentations of concussion injuries in EDs.</p>","PeriodicalId":11604,"journal":{"name":"Emergency Medicine Australasia","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the effectiveness of the maximum permitted dose of midazolam in seizure termination: Insights from New South Wales, Australia 评估咪达唑仑最大允许剂量在终止癫痫发作方面的有效性:澳大利亚新南威尔士州的启示。
IF 1.7 4区 医学 Q2 EMERGENCY MEDICINE Pub Date : 2024-06-03 DOI: 10.1111/1742-6723.14432
Pieter Francsois Fouche PhD, Martin Nichols MHlthSc, Raquel Abrahams BHSc, Kristina Maximous BHSc, Jason Bendall MBBS, PhD

Objective

Out-of-hospital seizures demand rapid management. Midazolam plays a key role in stopping seizures. At times the first dose of midazolam proves insufficient, necessitating additional doses. Within the New South Wales Ambulance (NSWA) service, the upper limit for midazolam administration is set at 15 mg. However, the outcomes and safety of using midazolam at this maximum dosage have not been thoroughly investigated.

Methods

A retrospective analysis of out of hospital electronic health records from New South Wales, Australia, over the year 2022, was conducted. The study manually reviewed cases where adult patients received the maximum dose of midazolam for seizure management by paramedics. It focused on seizure cessation success rates and the incidence of adverse effects to evaluate the clinical implications of high-dose midazolam administration.

Results

Of 818 790 individual attendances by NSWA clinicians, a total of 11 392 (1.4%) adults had seizures noted, of which midazolam was administered in 2565 (22.5%). An algorithm shows that in 2352 (91.7%) instances the midazolam was associated with the apparent termination of seizures. Analysis revealed that 176 (1.5%) proportion of all adult's seizure patients required the maximum dose of midazolam for seizure control. These higher doses successfully terminate seizures in about half of the instances. AEs following the maximum dose of midazolam included hypoxia in 26.7% of patients and respiratory depression in 9.7%, indicating significant side effects at higher dosages.

Conclusion

In New South Wales, Australia, administering the maximum dose of midazolam to seizure patients is rare but proves effective in approximately half of the refractory seizure cases. Therefore, assessing the potential for additional doses of midazolam or the use of a second-line agent is advisable.

目的:院外癫痫发作需要快速处理。咪达唑仑在阻止癫痫发作方面发挥着关键作用。有时,首剂咪达唑仑剂量不足,需要追加剂量。在新南威尔士救护车(NSWA)服务中,咪达唑仑的用药上限被设定为 15 毫克。然而,在这一最大剂量下使用咪达唑仑的效果和安全性尚未得到深入研究:研究对澳大利亚新南威尔士州 2022 年的院外电子健康记录进行了回顾性分析。该研究手动审查了成人患者接受最大剂量咪达唑仑治疗的病例。研究重点关注癫痫发作的成功率和不良反应的发生率,以评估大剂量咪达唑仑用药的临床意义:在国家社会福利署临床医生的 818 790 次个人就诊中,共有 11 392 人(1.4%)的成年人癫痫发作,其中 2565 人(22.5%)服用了咪达唑仑。算法显示,在 2352 例(91.7%)中,咪达唑仑与明显终止癫痫发作有关。分析显示,在所有成人癫痫患者中,有 176 人(1.5%)需要最大剂量的咪达唑仑来控制癫痫发作。这些高剂量药物成功终止癫痫发作的情况约占一半。使用最大剂量咪达唑仑后出现的不良反应包括:26.7%的患者出现缺氧,9.7%的患者出现呼吸抑制,这表明使用较大剂量时会产生明显的副作用:在澳大利亚新南威尔士州,对癫痫患者施用最大剂量咪达唑仑的情况很少见,但对大约一半的难治性癫痫发作病例有效。因此,对增加咪达唑仑剂量或使用二线药物的可能性进行评估是明智之举。
{"title":"Evaluating the effectiveness of the maximum permitted dose of midazolam in seizure termination: Insights from New South Wales, Australia","authors":"Pieter Francsois Fouche PhD,&nbsp;Martin Nichols MHlthSc,&nbsp;Raquel Abrahams BHSc,&nbsp;Kristina Maximous BHSc,&nbsp;Jason Bendall MBBS, PhD","doi":"10.1111/1742-6723.14432","DOIUrl":"10.1111/1742-6723.14432","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Out-of-hospital seizures demand rapid management. Midazolam plays a key role in stopping seizures. At times the first dose of midazolam proves insufficient, necessitating additional doses. Within the New South Wales Ambulance (NSWA) service, the upper limit for midazolam administration is set at 15 mg. However, the outcomes and safety of using midazolam at this maximum dosage have not been thoroughly investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective analysis of out of hospital electronic health records from New South Wales, Australia, over the year 2022, was conducted. The study manually reviewed cases where adult patients received the maximum dose of midazolam for seizure management by paramedics. It focused on seizure cessation success rates and the incidence of adverse effects to evaluate the clinical implications of high-dose midazolam administration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 818 790 individual attendances by NSWA clinicians, a total of 11 392 (1.4%) adults had seizures noted, of which midazolam was administered in 2565 (22.5%). An algorithm shows that in 2352 (91.7%) instances the midazolam was associated with the apparent termination of seizures. Analysis revealed that 176 (1.5%) proportion of all adult's seizure patients required the maximum dose of midazolam for seizure control. These higher doses successfully terminate seizures in about half of the instances. AEs following the maximum dose of midazolam included hypoxia in 26.7% of patients and respiratory depression in 9.7%, indicating significant side effects at higher dosages.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In New South Wales, Australia, administering the maximum dose of midazolam to seizure patients is rare but proves effective in approximately half of the refractory seizure cases. Therefore, assessing the potential for additional doses of midazolam or the use of a second-line agent is advisable.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11604,"journal":{"name":"Emergency Medicine Australasia","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1742-6723.14432","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
‘Vitamin B17’: Killing more than cancer 维生素 B17杀死的不仅仅是癌症
IF 1.7 4区 医学 Q2 EMERGENCY MEDICINE Pub Date : 2024-05-28 DOI: 10.1111/1742-6723.14450
Ingrid Berling BMed, FACEM, PgD(Clin Tox), PhD, Jared Brown BPharm(Hons), MPH, GradCertClinEpi(ClinTox), Brendan Toy MBBCh, DA, Dip PEC

Objective

Vitamin B17 tablets are sold (online) as an alternative cancer therapy medication. Its use however is not benign, given that it is metabolised into hydrogen cyanide. We aimed to measure the number of calls received by the New South Wales Poisons Information Centre (NSW PIC) regarding Amygdalin exposures.

Methods

A retrospective review of all amygdalin/cyanogenic glycoside product ingestion exposure calls to NSW PIC between 2015 and 2022.

Results

There were 120 unique exposure calls. Eighty-two (68%) were regarding minor exposures, with the remaining 38 (32%) of calls involving patients who had either a signifcant history or symptoms to prompt referral to hospital or were already seeking advice from a treating hospital clinican.

Conclusion

There is a significant burden of concern generated from the misuse of cyanogenic glycoside products for cancer prevention and treatment, which can result in hospital admission carrying significant health risk and expenditure.

目的:维生素 B17 药片作为癌症治疗的替代药物在网上销售。然而,由于维生素 B17 会代谢成氰化氢,因此其使用并非无害。我们的目的是测量新南威尔士毒物信息中心(NSW PIC)接到的有关戊二醛暴露的电话数量:方法:对 2015 年至 2022 年期间新南威尔士州毒物信息中心接到的所有杏仁苷/氰苷产品摄入暴露电话进行回顾性审查:结果:共接到 120 个独特的暴露电话。82起(68%)涉及轻微接触,其余38起(32%)涉及有明显病史或症状的患者,这些患者需要转诊至医院,或已经在向治疗医院的临床医生寻求建议:结论:滥用氰苷产品预防和治疗癌症会带来巨大的负担,可能导致患者入院治疗,带来巨大的健康风险和开支。
{"title":"‘Vitamin B17’: Killing more than cancer","authors":"Ingrid Berling BMed, FACEM, PgD(Clin Tox), PhD,&nbsp;Jared Brown BPharm(Hons), MPH, GradCertClinEpi(ClinTox),&nbsp;Brendan Toy MBBCh, DA, Dip PEC","doi":"10.1111/1742-6723.14450","DOIUrl":"10.1111/1742-6723.14450","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Vitamin B17 tablets are sold (online) as an alternative cancer therapy medication. Its use however is not benign, given that it is metabolised into hydrogen cyanide. We aimed to measure the number of calls received by the New South Wales Poisons Information Centre (NSW PIC) regarding Amygdalin exposures.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective review of all amygdalin/cyanogenic glycoside product ingestion exposure calls to NSW PIC between 2015 and 2022.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were 120 unique exposure calls. Eighty-two (68%) were regarding minor exposures, with the remaining 38 (32%) of calls involving patients who had either a signifcant history or symptoms to prompt referral to hospital or were already seeking advice from a treating hospital clinican.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There is a significant burden of concern generated from the misuse of cyanogenic glycoside products for cancer prevention and treatment, which can result in hospital admission carrying significant health risk and expenditure.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11604,"journal":{"name":"Emergency Medicine Australasia","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1742-6723.14450","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141159996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effectiveness analysis of an ambulance service-operated specialised cardiac vehicle with mobile extracorporeal cardiopulmonary resuscitation capacity for out-of-hospital cardiac arrests in Queensland, Australia 对澳大利亚昆士兰州院外心脏骤停救护服务运营的具有移动体外心肺复苏能力的心脏专车进行成本效益分析。
IF 1.7 4区 医学 Q2 EMERGENCY MEDICINE Pub Date : 2024-05-28 DOI: 10.1111/1742-6723.14447
Tan N Doan PhD, Stephen Rashford MBBS, FACEM, Emma Bosley PhD

Objective

Extracorporeal CPR (E-CPR) has been primarily limited to the in-hospital setting. A few systems around the world have implemented pre-hospital mobile E-CPR in the form of a dedicated cardiac vehicle fitted with specialised equipment and clinicians required for the performance of E-CPR on-scene. However, evidence of the outcomes and cost-effectiveness of mobile E-CPR remain to be established. We evaluated the cost-effectiveness of a hypothetical mobile E-CPR vehicle operated by Queensland Ambulance Service in the state of Queensland, Australia.

Methods

We adapted our published mathematical model to estimate the cost-effectiveness of pre-hospital mobile E-CPR relative to current practice. In the model, a specialised cardiac vehicle with mobile E-CPR capability is deployed to selected OHCA patients, with eligible candidates receiving pre-hospital E-CPR in-field and rapid transport to the closest appropriate centre for in-hospital E-CPR. For comparison, non-candidates receive standard ACLS from a conventional ambulance response. Cost-effectiveness was expressed as Australian dollars ($, 2021 value) per quality-adjusted life year (QALY) gained.

Results

Pre-hospital mobile E-CPR improves outcomes compared to current practice at a cost of $27 323 per QALY gained. The cost-effectiveness of pre-hospital mobile E-CPR is sensitive to the assumption around the number of patients who are the targets of the vehicle, with higher patient volume resulting in improved cost-effectiveness.

Conclusions

Pre-hospital E-CPR may be cost-effective. Successful implementation of a pre-hospital E-CPR programme requires substantial planning, training, logistics and operational adjustments.

目的:体外心肺复苏(E-CPR)主要局限于院内环境。世界上已有少数系统实施了院前移动式心肺复苏术,其形式为配备有现场实施心肺复苏术所需的专用设备和临床医生的专用心脏车。然而,有关移动 E-CPR 的效果和成本效益的证据仍有待确定。我们对澳大利亚昆士兰州昆士兰救护中心运营的假想移动式 E-CPR 车的成本效益进行了评估:我们对已发布的数学模型进行了调整,以估算院前移动式 E-CPR 相对于当前实践的成本效益。在该模型中,一辆具有移动 E-CPR 功能的心脏专车被部署到选定的 OHCA 患者处,符合条件的患者在现场接受院前 E-CPR 并被快速运送到最近的适当中心进行院内 E-CPR。作为对比,非候选者则接受传统救护车响应的标准 ACLS。成本效益以每个质量调整生命年(QALY)获得的澳元($,2021 年值)表示:结果:与目前的做法相比,院前移动 E-CPR 可改善预后,每获得一个质量调整生命年的成本为 27 323 澳元。院前移动 E-CPR 的成本效益对车辆目标患者人数的假设很敏感,患者人数越多,成本效益越高:院前 E-CPR 可能具有成本效益。院前 E-CPR 计划的成功实施需要大量的规划、培训、后勤和操作调整。
{"title":"Cost-effectiveness analysis of an ambulance service-operated specialised cardiac vehicle with mobile extracorporeal cardiopulmonary resuscitation capacity for out-of-hospital cardiac arrests in Queensland, Australia","authors":"Tan N Doan PhD,&nbsp;Stephen Rashford MBBS, FACEM,&nbsp;Emma Bosley PhD","doi":"10.1111/1742-6723.14447","DOIUrl":"10.1111/1742-6723.14447","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Extracorporeal CPR (E-CPR) has been primarily limited to the in-hospital setting. A few systems around the world have implemented pre-hospital mobile E-CPR in the form of a dedicated cardiac vehicle fitted with specialised equipment and clinicians required for the performance of E-CPR on-scene. However, evidence of the outcomes and cost-effectiveness of mobile E-CPR remain to be established. We evaluated the cost-effectiveness of a hypothetical mobile E-CPR vehicle operated by Queensland Ambulance Service in the state of Queensland, Australia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We adapted our published mathematical model to estimate the cost-effectiveness of pre-hospital mobile E-CPR relative to current practice. In the model, a specialised cardiac vehicle with mobile E-CPR capability is deployed to selected OHCA patients, with eligible candidates receiving pre-hospital E-CPR in-field and rapid transport to the closest appropriate centre for in-hospital E-CPR. For comparison, non-candidates receive standard ACLS from a conventional ambulance response. Cost-effectiveness was expressed as Australian dollars ($, 2021 value) per quality-adjusted life year (QALY) gained.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Pre-hospital mobile E-CPR improves outcomes compared to current practice at a cost of $27 323 per QALY gained. The cost-effectiveness of pre-hospital mobile E-CPR is sensitive to the assumption around the number of patients who are the targets of the vehicle, with higher patient volume resulting in improved cost-effectiveness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Pre-hospital E-CPR may be cost-effective. Successful implementation of a pre-hospital E-CPR programme requires substantial planning, training, logistics and operational adjustments.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11604,"journal":{"name":"Emergency Medicine Australasia","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141159990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bedside urine testing for fentanyl in self-reported heroin users in a tertiary Brisbane emergency department 布里斯班一家三级医院急诊科对自报吸食海洛因者的床边尿液进行芬太尼检测。
IF 1.7 4区 医学 Q2 EMERGENCY MEDICINE Pub Date : 2024-05-27 DOI: 10.1111/1742-6723.14446
Keith Harris MBBCh, BSc, FACEM, Amanda G Holford MD, FACEM, Benjamin G Learmont BNNP, Katherine Z Isoardi BMed, FACEM

Objective

To determine if patients presenting to our toxicology unit following self-reported heroin use had positive urine immunoassay testing for fentanyl or its analogues.

Methods

Urine samples from consenting patients were tested at the bedside for the presence of opiates or fentanyl and its analogues.

Results

Over a 30-month period, 58 patients were recruited. All samples tested positive for opiates, but none tested positive for fentanyl or its analogues.

Conclusion

In patients presenting to our toxicology unit in Brisbane, we did not find any cases where the urine of patients self-reporting heroin exposure tested positive for fentanyl or its analogues.

目的确定自称吸食海洛因后到毒物科就诊的患者是否在尿液免疫测定中发现芬太尼或其类似物呈阳性:方法:在床旁对同意的患者尿液样本进行鸦片制剂或芬太尼及其类似物检测:在 30 个月的时间里,共招募了 58 名患者。所有样本的鸦片制剂检测结果均呈阳性,但芬太尼或其类似物检测结果均未呈阳性:结论:在布里斯班毒物科就诊的患者中,我们没有发现任何自称接触过海洛因的患者尿液中芬太尼或其类似物检测呈阳性的病例。
{"title":"Bedside urine testing for fentanyl in self-reported heroin users in a tertiary Brisbane emergency department","authors":"Keith Harris MBBCh, BSc, FACEM,&nbsp;Amanda G Holford MD, FACEM,&nbsp;Benjamin G Learmont BNNP,&nbsp;Katherine Z Isoardi BMed, FACEM","doi":"10.1111/1742-6723.14446","DOIUrl":"10.1111/1742-6723.14446","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To determine if patients presenting to our toxicology unit following self-reported heroin use had positive urine immunoassay testing for fentanyl or its analogues.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Urine samples from consenting patients were tested at the bedside for the presence of opiates or fentanyl and its analogues.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Over a 30-month period, 58 patients were recruited. All samples tested positive for opiates, but none tested positive for fentanyl or its analogues.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In patients presenting to our toxicology unit in Brisbane, we did not find any cases where the urine of patients self-reporting heroin exposure tested positive for fentanyl or its analogues.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11604,"journal":{"name":"Emergency Medicine Australasia","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1742-6723.14446","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Emergency Medicine Australasia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1